tiprankstipranks
PharmaTher Holdings Ltd (TSE:PHRM)
CNQX:PHRM

PharmaTher Holdings Ltd (PHRM) Stock Price & Analysis

9 Followers

PHRM Stock Chart & Stats

Day’s RangeC$0 - C$0
52-Week RangeC$0.08 - C$0.43
Previous CloseC$0.21
Volume109.56K
Average Volume (3M)109.27K
Market Cap
C$20.28M
Enterprise ValueC$16.99M
Total Cash (Recent Filing)C$3.29M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)-3.9
Beta0.84
Apr 25, 2024
EPS EstimateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding88,169,065
10 Day Avg. Volume148,019
30 Day Avg. Volume109,273
Standard Deviation0.48
R-Squared0.07
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)4.53
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

17.58%0.00%<0.01%82.42%
17.58% Insiders
<0.01% Other Institutional Investors
82.42% Public Companies and
Individual Investors

PHRM FAQ

What was PharmaTher Holdings Ltd’s price range in the past 12 months?
PharmaTher Holdings Ltd lowest stock price was C$0.08 and its highest was C$0.43 in the past 12 months.
    What is PharmaTher Holdings Ltd’s market cap?
    Currently, no data Available
    When is PharmaTher Holdings Ltd’s upcoming earnings report date?
    PharmaTher Holdings Ltd’s upcoming earnings report date is Apr 25, 2024 which is 2 days ago.
      How were PharmaTher Holdings Ltd’s earnings last quarter?
      PharmaTher Holdings Ltd released its earnings results on Jan 26, 2024. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.
        Is PharmaTher Holdings Ltd overvalued?
        According to Wall Street analysts PharmaTher Holdings Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does PharmaTher Holdings Ltd pay dividends?
          PharmaTher Holdings Ltd pays a Notavailable dividend of C$0.03 which represents an annual dividend yield of N/A. See more information on PharmaTher Holdings Ltd dividends here
            What is PharmaTher Holdings Ltd’s EPS estimate?
            PharmaTher Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does PharmaTher Holdings Ltd have?
            PharmaTher Holdings Ltd has 88,169,070 shares outstanding.
              What happened to PharmaTher Holdings Ltd’s price movement after its last earnings report?
              PharmaTher Holdings Ltd reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.882%.
                Which hedge fund is a major shareholder of PharmaTher Holdings Ltd?
                Currently, no hedge funds are holding shares in TSE:PHRM
                ---

                PharmaTher Holdings Ltd Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Positive
                20 days / 200 days
                Momentum
                59.79%
                12-Months-Change

                Fundamentals

                Return on Equity
                -88.18%
                Trailing 12-Months
                Asset Growth
                -55.87%
                Trailing 12-Months

                Company Description

                PharmaTher Holdings Ltd

                Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation, is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. Pharmather repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system.
                ---

                PHRM Stock 12 Months Forecast

                Average Price Target

                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","1":"C$1","-1":"-C$1","-0.5":"-C$0.5","0.5":"C$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2022","6":"Dec<br/>2022","9":"Mar<br/>2023","12":"May<br/>2023","25":"May<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.125,0.11538461538461539,0.10576923076923077,0.09615384615384615,0.08653846153846154,0.07692307692307693,0.0673076923076923,0.05769230769230768,0.04807692307692307,0.038461538461538464,0.02884615384615384,0.019230769230769218,0.009615384615384609,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.125,0.11538461538461539,0.10576923076923077,0.09615384615384615,0.08653846153846154,0.07692307692307693,0.0673076923076923,0.05769230769230768,0.04807692307692307,0.038461538461538464,0.02884615384615384,0.019230769230769218,0.009615384615384609,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.125,0.11538461538461539,0.10576923076923077,0.09615384615384615,0.08653846153846154,0.07692307692307693,0.0673076923076923,0.05769230769230768,0.04807692307692307,0.038461538461538464,0.02884615384615384,0.019230769230769218,0.009615384615384609,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.145,"date":1654041600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.135,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.125,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.11,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.08,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.065,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.14,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.165,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1681430400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.125,"date":1683244800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                PharmaTher Holdings Ltd
                Curis
                Daré Bioscience
                Karyopharm Therapeutics
                AstraZeneca
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis